---
title: "Denali Therapeutics Inc. (DNLI.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/DNLI.US.md"
symbol: "DNLI.US"
name: "Denali Therapeutics Inc."
industry: "Biotechnology"
---

# Denali Therapeutics Inc. (DNLI.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.denalitherapeutics.com](https://www.denalitherapeutics.com) |

## Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for ...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.32 | 406/604 | - | - | - |
| PB | 3.40 | 254/604 | 2.78 | 2.07 | 1.80 |
| Dividend Yield | 4.84% | 1/604 | 5.43% | 5.07% | 4.67% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-12T05:00:00.000Z

Total Analysts: **18**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 17 | 94% |
| Overweight | 1 | 6% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 20.19 |
| Highest Target | 40.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/DNLI.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/DNLI.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/DNLI.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.